Company family · HQ JP
Eisai: medicine shortages
4523 · Tokyo
As of 2 Nov 2026, 17 Eisai products have a reported shortage across 1 countries, covering 6 medicines.
Products short17rank #127 of 464
Medicines6active ingredients
Countries1/16
New in 90 days0-10 vs market pace
Typical duration11 monthsmedian so far
Manufacturing0%demand-driven 82%
Where
Which therapeutic classes
Why, compared with all companies
Manufacturing problemIncreased demandActive ingredient shortageDistribution or logisticsCommercial decision or withdrawalRegulatory or licensingOtherNot stated
Manufacturing problems point to the company's own supply chain; increased demand often follows a competitor's shortage or a demand shock.
When its current shortages began
Against its peers
Breadth vs depth
Further right: more products short. Higher: more different medicines affected.
Medicines short
| Medicine | Where this company is short | Products | Earliest start | Main reason | Short anywhere |
|---|---|---|---|---|---|
| Isosorbide Dinitrate | 5 | 15 Dec 2025 | Increased demand | 1/16 | |
| Flecainide | 4 | 1 Aug 2025 | Increased demand | 5/16 | |
| Theophylline | 3 | 1 Jun 2026 | Increased demand | 3/16 | |
| Rabeprazole | 2 | 11 May 2026 | Increased demand | 5/16 | |
| Azelastine | 1 | 4 Mar 2024 | Quality problem or recall | 3/16 | |
| Mecobalamin | 1 | 19 Feb 2025 | Other | 1/16 |
Shortage data describes supply, not company finances. A shortage can mean lost sales for the supplier or extra demand for its competitors. Nothing here is investment advice; tickers are for identification only and may be out of date.